NPS Pharmaceuticals, Inc. (NPSP)
-NasdaqGM 15.33 
0.43(2.89%) Jun 18, 4:00PM EDT
| Prev Close: | 14.90 |
|---|
| Open: | 15.04 |
|---|
| Bid: | N/A |
|---|
| Ask: | 25.00 x 300 |
|---|
| 1y Target Est: | 18.83 |
|---|
| Beta: | 0.61 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 14.91 - 15.40 |
|---|
| 52wk Range: | 6.87 - 16.47 |
|---|
| Volume: | 1,120,270 |
|---|
| Avg Vol (3m): | 2,094,980 |
|---|
| Market Cap: | 1.44B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.19 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Corporate Profile NPS PharmaceuticalsWILink(Mon Jun 17)
- InPlay: NPS Pharm: Initial findings from PARADOX, research analyzing the burden of Hypoparathyroidism, reveals collection of nearly 40 physical, cognitive, emotional symBriefing.com(Mon Jun 17)
- Findings Presented at ENDO 2013 Support Therapeutic Potential of Natpara® as Parathyroid Hormone Replacement Therapy in Patients with HypoparathyroidismBusiness Wire(Mon Jun 17)
- Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional SymptomsBusiness Wire(Mon Jun 17)
- Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional SymptomsBusiness Wire(Mon Jun 17)
- Findings Presented at ENDO 2013 Support Therapeutic Potential of Natpara® as Parathyroid Hormone Replacement Therapy in Patients with HypoparathyroidismBusiness Wire(Mon Jun 17)
- NPS Pharmaceuticals’ President and CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award in New JerseyBusiness Wire(Fri Jun 14)
- NPS Pharmaceuticals’ President and CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award in New JerseyBusiness Wire(Fri Jun 14)
- NPS Pharmaceuticals to present hypoparathyroidism datatheflyonthewall.com(Wed Jun 5)
- NPS Pharmaceuticals to Present Data from Natpara™ REPLACE Study and PARADOX Study at ENDO 2013, The Endocrine Society’s 95th Annual MeetingBusiness Wire(Wed Jun 5)
- NPS Pharmaceuticals to Present Data from Natpara™ REPLACE Study and PARADOX Study at ENDO 2013, The Endocrine Society’s 95th Annual MeetingBusiness Wire(Wed Jun 5)
- The Profitable Business of Developing Orphan Drugsat Motley Fool(Tue Jun 4)
- NPS Reaches New 52-Week High (NPSP)at TheStreet(Tue Jun 4)
- Jim Cramer: Buy US Airways, Honeywell, Dollar General, and These 2 Stocksat Wall St. Cheat Sheet(Mon Jun 3)
- NPS Pharmaceuticals: Don't Fret About The $295,000 Price Tagat Seeking Alpha(Mon Jun 3)
Press Releases
- Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional SymptomsBusiness Wire(Mon Jun 17)
- Pre-Market Analysis on GILD, NPSP, HALO, SNTS, and ITMNAccesswire(Thu May 30)
- StockCall Study on Gilead Sciences, NPS Pharma, InterMune, Seattle Genetics, and Halozyme TherapeuticsAccesswire(Wed Apr 24)
Key Statistics
| Forward P/E (1 yr): | 38.32 |
|---|
| P/S (ttm): | 12.97 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.18 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -2.50 |
|---|
Business Summary
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on pa...
View More